What is the role of mycophenolate mofetil (CellCept) and mycophenolic acid (Myfortic) in immunosuppression after pediatric transplantation?

Updated: Oct 18, 2019
  • Author: Randy P Prescilla, MD; Chief Editor: Mary C Mancini, MD, PhD, MMM  more...
  • Print


Mycophenolate mofetil (CellCept) and mycophenolic acid (Myfortic)

Mycophenolate mofetil (MMF) is an ester prodrug that is hydrolyzed to the active immune suppressor mycophenolic acid (MPA). MPA inhibits the activity of inosine monophosphate dehydrogenase, a key enzyme in the de novo pathway of guanosine nucleotide synthesis in B and T lymphocytes that slows their proliferative response.

The unique property of MMF is its lack of cardiovascular risk and chronic nephrotoxic adverse effects.

Adverse effects are primarily GI (eg, nausea and/or vomiting, diarrhea, gastritis, duodenitis, esophagitis, ulcers). Other adverse events were related to bone marrow suppression (eg, leukopenia, anemia, thrombocytopenia).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!